ADJUVANT THERAPY OF OVARIAN-CANCER WITH RADIOACTIVE MONOCLONAL-ANTIBODY

Fifty-two patients with epithelial ovarian cancer were treated with yt trium-90-labelled monoclonal antibody HMFG1 administered intraperitone ally following conventional surgery and chemotherapy as part of an ext ended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previ ously described. Following conventional surgery and chemotherapy, 21 o ut of the 52 patients had no evidence of residual disease and were reg arded as receiving treatment in an adjuvant setting. To date, two of t hese patients have died of their disease (follow-up 3-62 months, media n follow-up 35 months). This extended phase I-II study suggests that p atients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.